Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next>

  title={Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next>},
  author={Pere P. Simarro and Jean Jannin and Pierre Cattand},
  journal={PLoS Medicine},
While the number of new detected cases of HAT is falling, say the authors, sleeping sickness could suffer the "punishment of success," receiving lower priority by public and private health institutions. 

Figures and Tables from this paper

Contemporary and emerging strategies for eliminating human African trypanosomiasis due to Trypanosoma brucei gambiense: review
To review current and emerging tools for Gambiense HAT control and elimination, and propose strategies that integrate these tools with epidemiological evidence.
Rapid diagnostic test for sleeping sickness.
Data on a prototype rapid diagnostic test for sleeping sickness, or human African trypanosomiasis, is presented and a potentially life-threatening vectorborne disease of sub-Saharan Africa is presented.
International Scientific Council for Trypanosomiasis Research and Control (ISCTRC)
This study reports on an investigation on drug resistance development to Diminazine Aceturate, Homidium Bromide and Isometamidium Chloride by Trypanosoma congolense isolates from the Ghibe valley of
Time to put out the lights on sleeping sickness?
  • C. Nimmo
  • Medicine
    Travel medicine and infectious disease
  • 2010
Human African trypanosomiasis
Epidemiology, diagnosis, and treatment of one of the world’s most neglected diseases shows clear trends in survival and morbidity and disease progression.
Human African Trypanosomiasis: The Smoldering Scourge of Africa
Human African trypanosomiasis (HAT) or sleeping sickness is one of Africa’s classic tropical diseases. First case reports go back to the fourteenth century. Until recently the impact of HAT on health
Treatment outcomes for human African Trypanosomiasis in the Democratic Republic of the Congo: analysis of routine program data from the world’s largest sleeping sickness control program
An electronic database to enable the human African trypanosomiasis control program of the Democratic Republic of the Congo to generate data on treatment outcomes was developed and piloted in two provinces, Bandundu and Kasai Oriental.
Trypanosoma brucei gambiense in domestic livestock of Kogo and Mbini foci (Equatorial Guinea)
Objective  To evaluate Trypanosoma brucei gambiense infection in peri‐domestic livestock from Kogo and Mbini foci (Equatorial Guinea) in order to investigate its possible implication in the sleeping
Trypanosoma brucei gambiense infection in vervet monkeys: a potential model for early‐stage disease
Non‐human primates are important experimental models for human African trypanosomiasis and may provide clues to the origin of the disease.
Linking sustainable human and animal African trypanosomosis control with rural development strategies.
In illustrating these stages, the paper draws on examples of recent interventions to deal with the problems posed by T&T, highlighting the factors that determine success and sustainability.


Human African trypanosomiasis of the CNS: current issues and challenges.
  • P. Kennedy
  • Medicine
    The Journal of clinical investigation
  • 2004
The issues of diagnosis and staging of CNS disease, its neuropathogenesis, and the possibility of new therapies for treating late-stage disease are discussed.
Welcome to Ethiopia's Fly Factory
ENTOMOLOGYKALITI, ETHIOPIA-- One of the poorest countries in the world has an ambitious plan to eliminate the tsetse fly. But some scientists say it's a waste of money.
Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced
Molecular Dipstick Test for Diagnosis of Sleeping Sickness
HAT-PCR-OC is a promising new tool for diagnosis of sleeping sickness in laboratory settings, and the diagnostic format described here may have wider application for other infectious diseases.
Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Uganda
The N+E combination appears to be a promising first-line therapy that may improve treatment of sleeping sickness, although the results from this interrupted study do not permit conclusive interpretations.
Options for Field Diagnosis of Human African Trypanosomiasis
There is an urgent need for better tools for the field diagnosis of this neglected disease, and improved access to diagnosis and treatment for the population at risk remains the greatest challenge for the coming years.
Successful application of deltamethrin pour on to cattle in a campaign against tsetse flies (Glossina spp.) in the pastoral zone of Samorogouan, Burkina Faso.
1,500-2,000 head of cattle were treated with deltamethrin 1% Spot On in an area of high tsetse densities, notably of Glossina morsitans submorsitans, showing resistance of Trypanosoma congolense to all commercially available trypanocides.
Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series
N+E could be the most promising combination regimen available for sleeping sickness, and deserves further evaluation, according to analysis approach.